Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Marie L Huber, Laura Haynes, Chris Parker, Peter Iversen, Marie L Huber, Laura Haynes, Chris Parker, Peter Iversen

Abstract

Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. The manufacturer proposes that antigen-presenting cells exogenously activated by PAP induce endogenous T-cells to attack PAP-bearing prostate cancer cells. However, the lack of demonstrable tumor responses has prompted calls for scrutiny of the design of the trials in which sipuleucel-T demonstrated a 4-month survival benefit. Previously unpublished data from the sipuleucel-T trials show worse overall survival in older vs younger patients in the placebo groups, which have not been shown previously to be prognostic for survival in castration-resistant prostate cancer patients receiving chemotherapy. Because two-thirds of the cells harvested from placebo patients, but not from the sipuleucel-T arm, were frozen and not reinfused, a detrimental effect of this large repeated cell loss provides a potential alternative explanation for the survival "benefit." Patient safety depends on adequately addressing this alternative explanation for the trial results.

Figures

Figure 1
Figure 1
The manufacturing process and proposed mechanism for sipuleucel-T (3). A) The manufacturing process for sipuleucel-T is depicted. Mononuclear cells are harvested from the patient and shipped to the manufacturing facility (approximately 46% T cells, 7% B cells, 13% natural killer cells, and 25% monocytes) (4) on day 1. On days 2–3, cells are put through two buoyant density centrifugation steps before incubation for 36–48 hours with a chimeric antigen (PA2024), consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate antigen presentation, which is linked to the prostatic acid phosphatase (PAP) tumor-associated antigen. Cells are given a final wash on days 3–4 before shipment back to the clinic for reinfusion into the patient. This process is repeated every 2 weeks for a complete course of three cycles. B) The proposed mechanism for sipuleucel-T antitumor activity is given. The manufacturer proposes that during incubation on days 2–3, antigen-presenting cells (APCs) process and present the synthetic antigen PA2024 on their surface, thereby becoming activated. Upon reinfusion, these cells are hypothesized to activate endogenous T-cells, thereby stimulating them to attack PAP-bearing prostate cancer cells.

References

    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med. 2010;363(5):411–422.
    1. Longo D. New therapies for castration-resistant prostate cancer. New Engl J Med. 2010;363(5):479–481.
    1. March 2007 CTGT Advisory Committee Meeting FDA CMC Presentation, Slides 4 & 11. . Accessed December 3, 2011.
    1. March 2007 CTGT Advisory Committee Meeting CMC Briefing Document. . Accessed December 3, 2011.
    1. Wonnacott K, Moos M, Husain S, Finn T. CMC Review, BLA 125197, Sipuleucel-T. . Accessed December 3, 2011.
    1. Zhen B, Gupta G. FDA Statistical Review and Evaluation Sipuleucel-T. . Accessed December 3, 2011. Completed April 30, 2010.
    1. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–1237.
    1. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396–6403.
    1. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–1105.
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004;351(15):1502–1512.
    1. Fan C, George B, Bross P. FDA Clinical Review Sipuleucel-T. . Accessed December 3, 2011. Completed April 28, 2010.
    1. Burns EA, Lum LG, L’Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol. 1993;48(6):B231–B236.
    1. Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J Comp Pathol. 2010;142(suppl 1):s116–s119.
    1. Gravekamp C. The importance of the age factor in cancer vaccination at older age. Cancer Immunol Immunother. 2009;58(12):1969–1977.
    1. Pawelec G, Lustgarten J, Ruby C, Gravekamp C. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother. 2009;58(12):1907–1908.
    1. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–1468.
    1. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245.
    1. Higano C, Saad F, Somer B, et al. A phase 3 trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castrationresistant prostate cancer (CRPC) Presented at the 2009 Genitourinary Cancers Symposium; February 26–28, 2009; Orlando, FL. Abstract LBA150. . Accessed December 3, 2011.
    1. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959–1966.
    1. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int. 2010;106(7):966–973.
    1. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase 3 study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168(6):2439–2443.
    1. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010;28(7):1085–1087.
    1. Kantoff PW. Updated results of the IMPACT trial of sipuleucel-T for metastatic, castration-resistant prostate cancer. Presentation at the ASCO Genitourinary Cancers Symposium; March 5–7, 2010; San Francisco, CA.
    1. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate specific antigen, pain, and quality of life response and survival in the TAX-327 Study. Clin Cancer Res. 2008;14(9):2763–2767.
    1. Registry entry for first Phase III sipuleucel-T trial D9901 (n=127). . Accessed December 3, 2011.
    1. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5(7):1738–1744.
    1. Aspinall R, Del Giudice G, Effros R, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing. 2007;4(1)
    1. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens. 2007;70(3):179–189.
    1. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol. 2005;17(5):468–475.
    1. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007;42(5):400–406.
    1. Schindowski K, Fröhlich L, Maurer K, Müller WE, Eckert A. Age-related impairment of human T lymphocytes’ activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev. 2002;123(4):375–390.
    1. Song L, Kim Y, Chopra R, et al. Age-related effects in T cell activation and proliferation. Exp Gerontol. 1993;28(4–5):313–321.
    1. Borrego F, Alonso MC, Galiani MD. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999;34(2):253–265.
    1. Kiertscher S, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000;164(3):1269–1276.
    1. Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocyte are differently regulated in elderly. Clin Immunol. 2007;122(2):220–228.
    1. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T cell/B cell interactions in human lymph nodes. Immunology. 2005;114(1):37–43.
    1. Mo R, Chen J, Han Y. T cell chemokine receptor expression in aging. J Immunol. 2003;170(2):895–904.
    1. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227–236.
    1. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005;17(2):180–186.
    1. Taub D, Longo D. Insights into thymic aging and regeneration. Immunol Rev. 2005;205(1):72–93.
    1. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010;1197(1):158–165.
    1. Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, Malaguarnera M. Immunosenescence and cancer: a review. Arch Gerontol Geriatr. 2001;32(2):77–93.
    1. Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res. 2008;68(13):5423–5431.
    1. Zhang HG, Grizzle WE. Aging, immunity, and tumor susceptibility. Immunol Allergy Clin North Am. 2003;23(1):83–102.
    1. Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev. 2005;205(1):5–6.
    1. Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174(11):7446–7452.
    1. Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol. 2010;184(12):6739–6745.
    1. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol. 1997;9(6):339–346.
    1. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–2357.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe